Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $48.30 USD
Change Today -0.36 / -0.74%
Volume 143.3K
NVZMY On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

novozymes a/s-unspons adr (NVZMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $51.11
52 Week Low
10/16/14 - $38.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

novozymes a/s-unspons adr (NVZMY) Related Businessweek News

No Related Businessweek News Found

novozymes a/s-unspons adr (NVZMY) Details

Novozymes A/S produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. The company offers solutions for the agriculture industry, including enzymes to enhance digestibility and nutritional value of animal feed; microbial solutions to maintain water quality, limit risks of disease, and enhance yields in aquaculture; and microbial-based biofertility, biocontrol, and bioyield enhancer products to naturally produce healthier crops and enhance yields. It also provides a portfolio of enzymes for application in biofuel production; recombinant products and technologies to the medical device and drug delivery market; and food and beverages enzymes for applications in baking, brewing, dairy, distilling, flavor enhancement, food specialties, health and nutrition, juice, meat processing, oils and fats, starch, and wine industries. In addition, the company offers household care enzyme and microbial agents for use in cleaning solutions, dishwashing, and laundry; enzymes for biopreparation, degreasing, and re-bating of leather; enzymes for pulp and paper production processes, such as bleach boosting, deinking, drainage enhancement, effluent control, pitch control, refining, slime control, starch modification, and stickies control; enzymatic solutions for processing textiles; and microbial solutions for biological wastewater treatment. Novozymes A/S has a strategic alliance with Monsanto Company to discover, develop, and sell microbial solutions for farmers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

6,486 Employees
Last Reported Date: 04/23/15
Founded in 1925

novozymes a/s-unspons adr (NVZMY) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr9.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.9M
Executive Vice President of Business Operatio...
Total Annual Compensation: kr5.4M
Executive Vice President of Research & Develo...
Total Annual Compensation: kr6.0M
Executive Vice President of Supply Operations
Total Annual Compensation: kr5.9M
Compensation as of Fiscal Year 2014.

novozymes a/s-unspons adr (NVZMY) Key Developments

Novozymes to Supply Enzyme Technology for New Biorefinery in Finland

Novozymes has signed an agreement to supply enzyme technology to a new biorefinery in Kajaani, Finland. Being built by St1 Biofuels and co-located at a sawmill site, the facility will use sawdust from softwood as feedstock to produce cellulosic ethanol at commercial scale in regions having abundance of softwood, such as the Northern Hemisphere. The process uses steam-explosion to open up sawdust's cellulosic structures, followed by enzymatic hydrolysis to extract the sugars for ethanol fermentation. The softwood comes from trees like pine that have needles instead of leaves.

Novozymes A/S Presents at Citi 2015 Global Consumer Conference, May-27-2015 through May-28-2015

Novozymes A/S Presents at Citi 2015 Global Consumer Conference, May-27-2015 through May-28-2015. Venue: The Plaza, a Fairmont Managed Hotel, Fifth Avenue at Central Park South, New York, NY 10019, United States. Presentation Date(s): May-27-2015. May-28-2015.

Novozymes A/S Reports Unaudited Group Financial Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year 2015

Novozymes A/S reported unaudited group financial results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of DKK 3,579 million against DKK 3,033 million for the same period of last year. EBITDA was DKK 1,206 million against DKK 1,167 million a year ago. Operating profit/EBIT was DKK 979 million against DKK 923 million for the same period of last year. Profit before tax was DKK 912 million against DKK 902 million for the same period of last year. Net profit attributable to shareholders of the company was DKK 706 million or DKK 2.29 per diluted share against DKK 693 million or DKK 2.18 per diluted share for the same period of last year. Free cash flow before acquisitions was DKK 610 million against DKK 2,230 million a year ago. Return on equity was 25.1% against 25.6% a year ago. Cash flow from operating activities was DKK 762 million against DKK 1,896 million a year ago. The lower operating cash flow was mainly a result of The BioAg Alliance agreement, which had a significant positive impact on operating cash flow in the first quarter of 2014. Purchase of property, plant and equipment was DKK 153 million against DKK 85 million a year ago. Free cash inflow was DKK 575 million against DKK 2,225 million a year ago. Free cash flow before acquisitions was DKK 610 million compared with DKK 2,230 million in the first quarter of 2014. Free cash flow was negatively impacted by The BioAg Alliance agreement, higher net investments and higher net working capital, driven by currency adjustments. Net interest-bearing debt was DKK 210 million at March 31, 2015, compared with a net positive cash holding of DKK 716 million at year-end 2014. The company revised earnings guidance for the year 2015. The company now expects sales growth of 16%-18% compared to previous guidance of 13%-15%, net profit growth of 11%-13% compared to previous guidance of 10%-12%. The increased expectations are a result of higher EBIT growth and expectations of a slightly lower tax rate than in 2014. Free cash flow before acquisitions is expected to be between DKK 2,500 million-DKK 2,700 million. The effective tax rate is expected to be 22-23%. The outlook for 2015 remains positive and is adjusted only for currency developments since the previous guidance in January. EBIT growth is now expected to be 15%-17%, up from 12%-14% at previous guidance as a result of the increased expectations for sales growth in DKK.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVZMY:US $48.30 USD -0.36

NVZMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chr Hansen Holding A/S kr331.60 DKK -3.00
Ebro Foods SA €17.17 EUR -0.005
EMS-Chemie Holding AG SFr.400.25 CHF -4.75
Kerry Group PLC €68.00 EUR -0.80
Sensient Technologies Corp $67.70 USD -0.53
View Industry Companies

Industry Analysis


Industry Average

Valuation NVZMY Industry Range
Price/Earnings 41.4x
Price/Sales 8.0x
Price/Book 9.2x
Price/Cash Flow 34.3x
TEV/Sales 6.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOZYMES A/S-UNSPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at